Development of new oral cancer treatment as molecular target for antiapoptosis protein and NF-kB
Development of new oral cancer treatment as molecular target for antiapoptosis protein and NF-kB
批准号:
21592556
负责人:
TAMATANI Tetsuya
金额:
$3.0万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2009
资助国家:
日本
项目状态:
已结题
起止时间:
2009 至 2011
中文摘要
XIAP是凋亡蛋白家族的一员,通过阻断caspase介导的细胞凋亡与细胞存活相关。XIAP在多种恶性肿瘤中表达。据报道,在各种恶性肿瘤中,XIAP的过表达是一个较差的预后因素。本研究旨在探讨XIAP蛋白在口腔鳞状细胞癌(OSCC)中的表达,并探讨其表达与临床分期、组织学分化及侵袭方式的关系。本研究采用人OSCC细胞系。正常牙龈上皮细胞作为对照。western blot检测培养细胞XIAP、cIAPs及survivin的表达。从85例手术或活检后的OSCC患者中获得组织标本。免疫组化法检测其表达。在所有癌细胞中都检测到这些蛋白的表达,但在正常细胞中没有。85例OSCC的免疫组化分析显示,73例(86%)OSCC表达XIAP。XIAP表达与临床分期、侵袭方式分型无相关性。XIAP表达与组织学分化之间存在显著差异。无染色和弱染色癌多数分化良好。相比之下,在低分化癌中经常发现强烈而广泛的染色。
英文摘要
XIAP is a member of the inhibitor of apoptosis protein family, which is associated with cell survival by blocking caspase-mediated apoptosis. XIAP is expressed in various malignant tumors. The overexpression of XIAP has been reported to be a poorer prognostic factor in various malignancies. present study were to evaluate the expression of XIAP protein in oral squamous cell carcinoma(OSCC) and to elucidate the relationships among the XIAP expression, clinical stages, histological differentiation and classification of invasion mode. human OSCC cell lines were used in this study. Normal gingival epithelial cells served as control. XIAP, cIAPs and survivin expressions of cultured cells wert detected by western blot. Tissue specimens were obtains from 85 patients with OSCC after surgery or biopsy. Their expression was detected by an immunohistochemical method. The expression of those proteins was detected in all cancer cells, but not in normal cells. Immunohistochemical analysis of 85 cases of OSCC showed that 73(86%) cases expressed XIAP. There was no relationship between XIAP expression and clinical stages, or classification of invasion mode. There were significant differences between XIAP expression and histological differentiation. Most of non-staining and weakly staining of cancer was well differentiated. In contrast, intense and extensive staining was frequently found in poorly differentiated cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Increased anti-tumor effects of sequential docetaxel followed by 5-FU treatment against human oral cancer cells
序贯多西紫杉醇和 5-FU 治疗对人类口腔癌细胞的抗肿瘤作用增强
DOI:
--
发表时间:
2010
期刊:
影响因子:
--
作者:
[Tetsuya Tamatani, et al.]
通讯作者:
et al.
口腔扁平上皮癌におけるsurvivinの発現に関する検討
口腔鳞癌中survivin表达的研究
DOI:
--
发表时间:
2010
期刊:
影响因子:
--
作者:
[大木宏介, 他, 玉谷哲也]
通讯作者:
玉谷哲也
Increased anti-tumor effects of sequential docetaxel followed by 5-FUtreatment against human oral cancer cells
序贯多西紫杉醇和 5-FU 治疗对人类口腔癌细胞的抗肿瘤作用增强
DOI:
--
发表时间:
2010
期刊:
影响因子:
--
作者:
[森士朗, 他, 玉谷哲也]
通讯作者:
玉谷哲也
Anti-tumor efficacy of sequential treatment with docetaxel and 5-FU combination therapy against human oral cancer cells
多西他赛联合5-FU序贯治疗对人口腔癌细胞的抗肿瘤作用
DOI:
--
发表时间:
2009
期刊:
影响因子:
--
作者:
[Tarannum Ferdous, 他]
通讯作者:
他
The expression of survivin in human oral squamous cell carcinomaand its relationship with clinical factors
Survivin在人口腔鳞癌中的表达及其与临床因素的关系
DOI:
--
发表时间:
2011
期刊:
影响因子:
--
作者:
[森士朗, 李麗, 堀江佐知子, 渡邉夕紀子, 大木宏介, 宮下仁, 川村仁, 森川秀広, 小玉哲也, 玉谷哲也]
通讯作者:
玉谷哲也
共 6 条
Analysis of PARP as nobel potencial therapeutic targets in oral cancer
-
批准号:24593036
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.49万
-
财政年份:2012
-
负责人:TAMATANI Tetsuya
-
依托单位:
Development of new therapy using molecular target drug for VEGF and proteasome inhibitor against oral cancer
-
批准号:19592338
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.91万
-
财政年份:2007
-
负责人:TAMATANI Tetsuya
-
依托单位:
海外基金